The results from a large Randomised Clinical Trial investigating the impact of a commercially available mastitis vaccine ('Startvac', HIPRA UK) for dairy herds has recently been published in the Journal of Dairy Science. The research, carried out by Dr Andrew Bradley and the team at QMMS Ltd, looked at more than 3000 cows in 7 herds based in the south-west, and measured clinical mastitis and cell count outcomes, as well as using bacteriology to identify infected cows. Whilst the vaccine did not reduce overall mastitis rate or cell count parameters, the odds of a clinical mastitis case presenting with severe signs were 40% lower in cows receiving the vaccine 'on label'. Interestingly, vaccinated cows gave significantly more milk and milk solids in the first 120 days of lactation. The paper is published 'open access' and can be viewed here.

QMMS logo

Twitter...